Hints and tips:
...“We know we have a responsibility to find solutions and we are fully aware that with this pandemic we cannot expect to do business as usual,” said IFPMA’s Thomas Cueni....
...Potential big earners passed include Sanofi and Regeneron’s Dupixent (eczema), Roche’s Ocrevus (multiple sclerosis) and AstraZeneca’s durvalumab (cancer)....
International Edition